DXCM News and Press, DexCom Inc. From 02/09/23

DexCom ( NASDAQ: DXCM ) is up 4% in after-hours trading after the continuous glucose monitor company saw its Q4 2022 financial results beat on the bottom line . Non-GAAP net income $136.3M ($0.34 per diluted share) for the quarter compared to a net loss of $2.4M  ($0.01) ...

DexCom press release ( NASDAQ: DXCM ): Q4 Non-GAAP EPS of $0.34 beats by $0.06 . Revenue of $815.2M (+16.8% Y/Y) in-line. 2023 Annual Guidance The company is reiterating guidance for fiscal year 2023 revenue, Non-GAAP Gross Profit Margin, and Non-GAAP Operating Margin,...

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights: Revenue grew 17% versus the same quarter of the prior year to $815.2 million on a reported basis and 20% on a...

DexCom ( NASDAQ: DXCM ) is scheduled to announce Q4 earnings results on Thursday, February 9th, after market close. The consensus EPS Estimate is $0.28 (-58.8% Y/Y) and the consensus Revenue Estimate is $814.52M (+16.7% Y/Y). Over the last 2 years, DXCM has beaten EPS estima...

Super Bowl commercial announces US launch of the next-generation Dexcom G7 CGM System, the most accurate, 1 easy to use CGM available that helps people with diabetes gain greater control of their health New ad, airing during the second quarter, raises critical awareness on one of the ...

Summary DexCom is young, innovative, admired, and (consequently) highly valued. Embecta is old, lethargic, lacks coverage, and (consequently) lowly valued. Growth and value investors may find respective equities interesting. I use DXCM and EMBC as a lens to view developments in ...

Last year's bear market made many victims among even the most prominent corporations although growth stocks fared even worse than other categories of equities. But some growth-oriented companies managed to buck the trend. Among this small group of outperformers are two healthcare leaders: biotech...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Global Growth Strategy takes a diversified appr...

Initiating coverage on medical equipment makers for diabetes, Wolfe Research granted an Outperform rating for CGM device maker DexCom ( NASDAQ: DXCM ), and Peer Perform ratings for insulin pump makers Tandem Diabetes ( NASDAQ: TNDM ) and Insulet Corporation ( NASDAQ: PODD ...